EP Patent

EP3996696A1 — Treatment of glycogen storage disease (gsd)

Assigned to Institut National de la Sante et de la Recherche Medicale INSERM · Expires 2022-05-18 · 4y expired

What this patent protects

The invention relates to a kit of parts comprising (i) pharmacological chaperones or a pharmaceutically acceptable salt thereof and (ii) a therapeutic acid-alpha glucosidase (GAA) polypeptide or a nucleic acid molecule encoding a therapeutic GAA polypeptide, wherein said pharmaco…

USPTO Abstract

The invention relates to a kit of parts comprising (i) pharmacological chaperones or a pharmaceutically acceptable salt thereof and (ii) a therapeutic acid-alpha glucosidase (GAA) polypeptide or a nucleic acid molecule encoding a therapeutic GAA polypeptide, wherein said pharmacological chaperones are 1-deoxynojirimycin (DNJ) or a derivative thereof and ambroxol (ABX) or a derivative thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP3996696A1
Jurisdiction
EP
Classification
—
Expires
2022-05-18
Drug substance claim
No
Drug product claim
No
Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.